The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
The first such initiative under the MoU will involve establishing a Centre of Excellence for Renal Sciences at the Tomo Riba Institute of Health & Medical Sciences (TRIHMS)
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Subscribe To Our Newsletter & Stay Updated
